Search

Displaying results 1761 - 1770 of 10000 in total
  1. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. … Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was

  2. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    a range of symptoms including bone pain, hematologic abnormalities, and end-organ damage. … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development

  3. Drug

    Idursulfase

    go.drugbank.com/drugs/DB01271
    ApprovedInvestigational

    Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine.

    Synonyms: Alpha-L-iduronate sulfate sulfatase
  4. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    [A7117] Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures … Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.

  5. Drug

    Debrisoquine

    go.drugbank.com/drugs/DB04840
    Approved

    An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. … They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

  6. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo. … Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology

  7. Drug

    Bordetella pertussis pertactin antigen

    go.drugbank.com/drugs/DB10789
    ApprovedInvestigational

    Bordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].

    Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Covaxis Injektionssuspension in einer Fertigspritze
  8. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1

  9. Drug

    Potassium alum

    go.drugbank.com/drugs/DB09087
    ApprovedWithdrawn

    [L1070] It is an inorganic salt, also called potassium aluminum sulfate with a formula of AlK(SO4)2 that is predominantly produced in the dodecahydrate form (AlK(SO4)2 * 12H2O). … Potassium alum is formed by large, transparent crystals that are used in different products like food or drugs as a buffer, neutralizing or forming agent.[T60]

    Products: Gingibraid W Alum Pot Sulf 0a 0.25mg/2.5cm, Gingibraid W Alum Pot Sulf 1a 0.35mg/2.5cm
  10. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. … It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]

    Categories: Compounds used in a research, industrial, or household setting